

Performance characteristics of five immunoassays for S benchmark comparison

Lancet Infectious Diseases, The
20, 1390-1400

DOI: [10.1016/s1473-3099\(20\)30634-4](https://doi.org/10.1016/s1473-3099(20)30634-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The complexities of SARS-CoV-2 serology. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1350-1351.	4.6	42
2	Modeling Donor Screening Strategies to Reduce the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission via Fecal Microbiota Transplantation. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa499.	0.4	3
3	An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. <i>Journal of Clinical Medicine</i> , 2020, 9, 3752.	1.0	30
4	Fast detection of SARS-CoV-2 RNA via the integration of plasmonic thermocycling and fluorescence detection in a portable device. <i>Nature Biomedical Engineering</i> , 2020, 4, 1159-1167.	11.6	159
5	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2020, 11, 610688.	2.2	190
6	Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	170
7	Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	64
8	SARS-COV-2 IgG antibody response in pregnant women at delivery. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 102041.	0.6	12
9	Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam. <i>Journal of Infection</i> , 2021, 82, e36-e37.	1.7	10
10	Technical considerations to development of serological tests for SARS-CoV-2. <i>Talanta</i> , 2021, 224, 121883.	2.9	27
11	Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. <i>New England Journal of Medicine</i> , 2021, 384, 533-540.	13.9	803
12	Comparison of three automatic chemiluminescent immunoassays for monitoring dynamic profile of SARS-CoV-2 IgG and IgM. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23681.	0.9	5
13	Immunoassays for anti-SARS-CoV-2 antibodies: recent insights. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e120.	4.6	4
14	Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test. <i>Clinical Chemistry</i> , 2021, 67, 742-752.	1.5	69
15	Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. <i>Nature Communications</i> , 2021, 12, 113.	5.8	115
16	High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond?. <i>Epidemiology and Infection</i> , 2021, 149, e39.	1.0	39
17	Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	3
19	SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals during the First Wave of the COVID-19 Pandemic. <i>Medicina (Lithuania)</i> , 2021, 57, 148.	0.8	3

#	ARTICLE	IF	CITATIONS
20	Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports. <i>International Health</i> , 2022, 14, 18-52.	0.8	11
22	Next-generation COVID-19 vaccines: here come the proteins. <i>Lancet, The</i> , 2021, 397, 643-645.	6.3	9
23	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
24	Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. <i>PLoS ONE</i> , 2021, 16, e0247852.	1.1	45
26	Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. <i>BMC Infectious Diseases</i> , 2021, 21, 187.	1.3	23
28	Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits. <i>Pathogens</i> , 2021, 10, 161.	1.2	23
31	Adaptation of Elecsys [®] anti-severe acute respiratory syndrome coronavirus-2 immunoassay to dried blood spots: proof of concept. <i>Bioanalysis</i> , 2021, 13, 161-167.	0.6	7
32	SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. <i>Transfusion</i> , 2021, 61, 862-872.	0.8	48
33	SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. <i>Viruses</i> , 2021, 13, 247.	1.5	28
34	Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. <i>PLoS ONE</i> , 2021, 16, e0249247.	1.1	38
35	Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab122.	0.4	13
37	A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies. <i>Nature Communications</i> , 2021, 12, 1806.	5.8	36
38	Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. <i>Microorganisms</i> , 2021, 9, 733.	1.6	22
41	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	5.8	54
42	Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2235-2241.	1.3	8
43	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. <i>EBioMedicine</i> , 2021, 65, 103259.	2.7	61
47	Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys [®] high throughput immunoassay. <i>Journal of Clinical Virology</i> , 2021, 136, 104739.	1.6	44
49	Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021, 27, 928-931.	2.0	104

#	ARTICLE	IF	CITATIONS
51	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
52	Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings. <i>Journal of Clinical Medicine</i> , 2021, 10, 1605.	1.0	5
53	Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe. <i>Journal of Clinical Medicine</i> , 2021, 10, 1909.	1.0	1
55	Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. <i>American Journal of Transplantation</i> , 2021, 21, 2876-2884.	2.6	32
56	Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk.. <i>EClinicalMedicine</i> , 2021, 34, 100835.	3.2	20
57	A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. <i>JCI Insight</i> , 2021, 6, .	2.3	39
58	Performance Evaluation of the Siemens SARS-CoV-2 Total Antibody and IgG Antibody Test. <i>Laboratory Medicine</i> , 2021, 52, e147-e153.	0.8	9
59	Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers. <i>Scientific Reports</i> , 2021, 11, 7614.	1.6	26
61	An international comparison of anti-SARS-CoV-2 assays used for seroprevalence surveys from blood component providers. <i>Vox Sanguinis</i> , 2021, 116, 946-954.	0.7	6
62	Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK. <i>Emerging Infectious Diseases</i> , 2021, 27, 1155-1158.	2.0	13
63	Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. <i>JAMA Internal Medicine</i> , 2021, 181, 450.	2.6	273
65	Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	97
66	Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain. <i>Journal of Clinical Virology</i> , 2021, 137, 104784.	1.6	30
68	IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4951.	1.8	20
70	Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study. <i>European Journal of Cancer</i> , 2021, 148, 359-370.	1.3	16
71	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
72	Misdiagnosis of SARS-CoV-2: A Critical Review of the Influence of Sampling and Clinical Detection Methods. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 36.	1.3	7
73	Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results. <i>Clinical Chemistry</i> , 2021, 67, 977-986.	1.5	9

#	ARTICLE	IF	CITATIONS
74	Population (Antibody) Testing for COVID-19—Technical Challenges, Application and Relevance, an English Perspective. <i>Vaccines</i> , 2021, 9, 550.	2.1	6
75	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 2049-2059.	6.3	391
77	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. <i>Annals of Intensive Care</i> , 2021, 11, 73.	2.2	9
79	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. <i>JAMA Internal Medicine</i> , 2021, 181, 672.	2.6	236
80	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. <i>European Journal of Cancer</i> , 2021, 148, 328-339.	1.3	14
81	SARS-CoV-2 antibody immunoassays in serial samples reveal earlier seroconversion in acutely ill COVID-19 patients developing ARDS. <i>PLoS ONE</i> , 2021, 16, e0251587.	1.1	2
82	Insights into household transmission of SARS-CoV-2 from a population-based serological survey. <i>Nature Communications</i> , 2021, 12, 3643.	5.8	61
83	The prevalence of SARS-CoV-2 antibodies in triage-negative patients and staff of a fertility setting from lockdown release throughout 2020. <i>Human Reproduction Open</i> , 2021, 2021, hoab028.	2.3	2
84	Sero-Prevalence of SARS-CoV-2 Antibodies in High-Risk Populations in Vietnam. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6353.	1.2	8
85	Long-Term Longitudinal Evaluation of Six Commercial Immunoassays for the Detection of IgM and IgG Antibodies against SARS CoV-2. <i>Viruses</i> , 2021, 13, 1244.	1.5	3
86	Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	106
87	Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	113
88	ENE-COVID nationwide serosurvey served to characterize asymptomatic infections and to develop a symptom-based risk score to predict COVID-19. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 240-254.	2.4	12
89	In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1505-1518.	1.8	53
90	Performance characteristics of five SARS-CoV-2 serological assays: Clinical utility in health-care workers. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 496-504.	0.8	6
91	Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study. <i>EBioMedicine</i> , 2021, 68, 103414.	2.7	17
92	Diagnostic and analytical performance evaluation of ten commercial assays for detecting SARS-CoV-2 humoral immune response. <i>Journal of Immunological Methods</i> , 2021, 493, 113043.	0.6	10
93	Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. <i>European Respiratory Journal</i> , 2022, 59, 2100285.	3.1	14

#	ARTICLE	IF	CITATIONS
94	Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity. PLoS ONE, 2021, 16, e0253889.	1.1	6
95	Head-to-head validation of six immunoassays for SARS-CoV-2 in hospitalized patients. Journal of Clinical Virology, 2021, 139, 104821.	1.6	10
96	Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 2021, 27, 1370-1378.	15.2	260
97	A Multicenter Cohort Study From India of 75 Kidney Transplants in Recipients Recovered After COVID-19. Transplantation, 2021, 105, 1423-1432.	0.5	21
98	Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. The Lancet Healthy Longevity, 2021, 2, e362-e370.	2.0	60
99	Retrospective serosurveillance for anti-SARS-CoV-2 immunoglobulin during a time of low prevalence: A cautionary tale. Journal of Infection, 2021, 83, 119-145.	1.7	1
101	SARS-CoV-2 anti-nucleocapsid assay performance in healthcare workers at baseline and 6 months. Irish Journal of Medical Science, 2022, 191, 1089-1092.	0.8	7
104	Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet, The, 2021, 398, 385-387.	6.3	366
106	Retrospective SARS-CoV-2 IgG screening during the first wave (March-June 2020) of the COVID-19 pandemic in the United Kingdom. Journal of Medical Virology, 2021, 93, 6050-6053.	2.5	2
107	Serological survey of antibodies against SARS-CoV-2 in dogs and cats, Thailand. Transboundary and Emerging Diseases, 2022, 69, 2140-2147.	1.3	27
108	Evaluation of Three Commercial and Two Non-Commercial Immunoassays for the Detection of Prior Infection to SARS-CoV-2. journal of applied laboratory medicine, The, 2021, 6, 1561-1570.	0.6	14
109	Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time. ELife, 2021, 10, .	2.8	91
110	Humoral response to SARS-CoV-2 is well preserved and symptom dependent in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 3926-3935.	2.6	12
111	Assessment of SARS-CoV-2 Infection among Healthcare Workers of a German COVID-19 Treatment Center. International Journal of Environmental Research and Public Health, 2021, 18, 7057.	1.2	6
112	Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination. Vaccines, 2021, 9, 840.	2.1	33
113	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	4.7	117
114	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. Clinical Infectious Diseases, 2022, 74, 1208-1219.	2.9	64
115	Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients. Scientific Reports, 2021, 11, 13780.	1.6	10

#	ARTICLE	IF	CITATIONS
116	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
118	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1489-1499.	1.9	32
119	Laboratory Diagnosis of SARS-CoV-2 Pneumonia. <i>Diagnostics</i> , 2021, 11, 1270.	1.3	20
121	Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. <i>Nature Microbiology</i> , 2021, 6, 1140-1149.	5.9	254
122	Seroprevalence of SARS-CoV-2 infection in health care workers of a teaching hospital in Belgium: self-reported occupational and household risk factors for seropositivity. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115414.	0.8	8
123	Reply to Schulte-Pelkum, J. Comment on Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> 2021, 9, 556. <i>Microorganisms</i> , 2021, 9, 1849.	1.6	3
124	Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 24-31.	0.9	57
126	Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0055921.	1.8	8
127	Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 316.	7.1	17
128	Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021. <i>Journal of Infection</i> , 2021, 83, 237-279.	1.7	15
129	Clinical performance of the Elecsys® anti-SARS-CoV-2 combined in an algorithm with two specific anti-IgG immunoassays for the evaluation of the serological response of patients with COVID-19 in a population with a high prevalence of infection. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 614-621.	0.8	1
130	SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020. <i>Pathology</i> , 2021, 53, 645-651.	0.3	8
131	SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications. <i>ACS Sensors</i> , 2021, 6, 2815-2837.	4.0	24
133	AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories. <i>Clinical Chemistry</i> , 2021, 67, 1188-1200.	1.5	20
134	Material strategies and considerations for serologic testing of global infectious diseases. <i>MRS Bulletin</i> , 2021, , 1-5.	1.7	3
135	Development and Evaluation of Quantitative Immunoglobulin G Enzyme-Linked Immunosorbent Assay for the Diagnosis of Coronavirus Disease 2019 Using Truncated Recombinant Nucleocapsid Protein as Assay Antigen. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9630.	1.2	4
137	COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves. <i>Progress in Pediatric Cardiology</i> , 2021, 62, 101407.	0.2	15
139	Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test. <i>Journal of Medical Virology</i> , 2022, 94, 335-341.	2.5	11

#	ARTICLE	IF	CITATIONS
140	Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms. <i>Micromachines</i> , 2021, 12, 1079.	1.4	11
142	Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. <i>Microbiology Spectrum</i> , 2021, 9, e0073321.	1.2	22
143	Ronapreve for prophylaxis and treatment of covid-19. <i>BMJ, The</i> , 2021, 374, n2136.	3.0	12
145	Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response. <i>journal of applied laboratory medicine, The</i> , 2022, 7, 57-65.	0.6	18
146	SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays. <i>Microbiology Spectrum</i> , 2021, 9, e0039121.	1.2	17
148	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. <i>PLoS ONE</i> , 2021, 16, e0257743.	1.1	13
149	An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. <i>PLoS ONE</i> , 2021, 16, e0258041.	1.1	10
150	Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Pathology Research and Practice</i> , 2021, 225, 153565.	1.0	8
151	Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship. <i>PLoS ONE</i> , 2021, 16, e0257452.	1.1	10
152	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100028.	0.4	2
153	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	0.9	6
154	Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e544-e553.	2.0	43
155	Absence of SARS-CoV-2 antibodies in pre-pandemic plasma from children and adults in Vietnam. <i>International Journal of Infectious Diseases</i> , 2021, 111, 127-129.	1.5	7
156	Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma. <i>Journal of Immunological Methods</i> , 2021, 497, 113104.	0.6	4
157	Ultra-fast, high throughput and inexpensive detection of SARS-CoV-2 seroconversion using Ni ²⁺ magnetic beads. <i>Analytical Biochemistry</i> , 2021, 631, 114360.	1.1	11
158	Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies. <i>Annals of Laboratory Medicine</i> , 2022, 42, 71-78.	1.2	6
159	Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1143-1154.	1.4	24
161	The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2021, 73, e699-e709.	2.9	235

#	ARTICLE	IF	CITATIONS
169	Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation: a brief commentary. <i>Vox Sanguinis</i> , 2021, 116, 493-496.	0.7	17
170	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	81
171	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	122
172	Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. <i>PLoS ONE</i> , 2020, 15, e0243025.	1.1	45
173	Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e179-e183.	1.4	15
174	SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	17
175	Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 415-418.	1.2	10
176	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 1849-1860.	1.9	16
177	Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. <i>European Journal of Immunology</i> , 2022, 52, 149-160.	1.6	15
178	Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. <i>European Journal of Cancer</i> , 2021, 159, 105-112.	1.3	36
180	Challenges of Diagnosing Viral Myocarditis in Adolescents in the Era of COVID-19 and MIS-C. <i>Case Reports in Pediatrics</i> , 2021, 2021, 1-7.	0.2	1
181	Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates. <i>Clinical Infectious Diseases</i> , 2022, 75, e764-e773.	2.9	5
183	COVID-19 in children and young adults with kidney disease: risk factors, clinical features and serological response. <i>Journal of Nephrology</i> , 2022, 35, 121-129.	0.9	7
184	Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. <i>Journal of General Virology</i> , 2021, 102, .	1.3	21
185	Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 102, 115561.	0.8	0
187	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. <i>Nature Medicine</i> , 2021, 27, 2127-2135.	15.2	450
188	Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal. <i>Emerging Infectious Diseases</i> , 2021, 27, 2878-2881.	2.0	9
189	Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. <i>International Immunopharmacology</i> , 2021, 101, 108215.	1.7	20

#	ARTICLE	IF	CITATIONS
190	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , 2021, 12, 6250.	5.8	88
193	Longitudinal Assessment of Symptoms and Risk of SARS-CoV-2 Infection in Healthcare Workers Across 5 Hospitals to Understand Ethnic Differences in Infection Risk. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
194	Sensitivity and specificity as clinical indicators of laboratory quality. <i>Laboratornaya Sluzhba</i> , 2020, 9, 5.	0.0	1
196	IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study. <i>HIV Medicine</i> , 2021, , .	1.0	3
197	Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia—A Case Report. <i>Vaccines</i> , 2021, 9, 1344.	2.1	26
199	Quantification and prognostic significance of interferon- γ secreting SARS-CoV-2 responsive T cells in hospitalised patients with acute COVID-19. <i>Journal of Infection</i> , 2021, , .	1.7	0
200	Are hospitals epicentres of COVID-19 transmission? Findings of serial serosurveys among healthcare workers from a tertiary hospital in South India. <i>Indian Journal of Medical Microbiology</i> , 2021, , .	0.3	1
202	A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval. <i>Clinical Infectious Diseases</i> , 2022, 75, e888-e891.	2.9	25
203	Kidney Transplant Recipient Behavior During the Early COVID-19 Pandemic: A National Survey Study in Norway. <i>Kidney Medicine</i> , 2022, 4, 100389.	1.0	2
204	Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers. <i>Journal of Biological Rhythms</i> , 2022, 37, 124-129.	1.4	42
205	Point-of-care diagnostics: recent developments in a pandemic age. <i>Lab on A Chip</i> , 2021, 21, 4517-4548.	3.1	34
206	Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients. <i>Transplant International</i> , 2021, 35, 10026.	0.8	9
207	Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study. <i>Transplantation</i> , 2022, 106, 842-852.	0.5	21
208	Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. <i>The Lancet Healthy Longevity</i> , 2022, 3, e13-e21.	2.0	85
209	An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees. <i>International Journal of Infectious Diseases</i> , 2022, 115, 116-125.	1.5	14
210	Long-Term Comparison of 7 SARS-CoV-2 Antibody Assays in the North Zealand Covid-19 Cohort. <i>Journal of Applied Laboratory Medicine</i> , The, 2022, 7, 711-726.	0.6	5
212	Survey of SARS-CoV-2 in dogs and cats in high-risk areas during the second wave of COVID-19 outbreak, Thailand. <i>Zoonoses and Public Health</i> , 2022, 69, 737-745.	0.9	19
213	Serological testing for SARS-CoV-2 antibodies in clinical practice: A comparative diagnostic accuracy study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2090-2103.	2.7	11

#	ARTICLE	IF	CITATIONS
214	Response to and outcomes of the Pfizer <scp>BNT162B2</scp> vaccine in hemodialysis patientsâ€™A prospective observational study. <i>Hemodialysis International</i> , 2022, 26, 216-222.	0.4	6
215	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. <i>Nature Communications</i> , 2022, 13, 153.	5.8	45
216	Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers. <i>Diagnostics</i> , 2022, 12, 205.	1.3	13
218	Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months. <i>Infectious Diseases Now</i> , 2022, 52, 68-74.	0.7	8
220	The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam. <i>IJID Regions</i> , 2022, 2, 137-140.	0.5	3
221	Social Media Efficacy in Crisis Management: Effectiveness of Non-pharmaceutical Interventions to Manage COVID-19 Challenges. <i>Frontiers in Psychiatry</i> , 2021, 12, 626134.	1.3	86
222	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2022, 399, 665-676.	6.3	280
223	Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies. <i>Frontiers in Medicine</i> , 2022, 9, 820151.	1.2	11
224	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. <i>Clinical Biochemistry</i> , 2022, 101, 19-25.	0.8	5
225	Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand. <i>BMC Infectious Diseases</i> , 2021, 21, 1213.	1.3	3
226	Variation in the COVID-19 infectionâ€™fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. <i>Lancet, The</i> , 2022, 399, 1469-1488.	6.3	165
227	Implementation and Extended Evaluation of the Euroimmun Anti-SARS-CoV-2 IgG Assay and Its Contribution to the United Kingdomâ€™s COVID-19 Public Health Response. <i>Microbiology Spectrum</i> , 2022, 10, e0228921.	1.2	2
228	Evaluation of the Performance of a Multiplexed Serological Assay in the Detection of SARS-CoV-2 Infections in a Predominantly Vaccinated Population. <i>Microbiology Spectrum</i> , 2022, 10, e0145421.	1.2	8
231	Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 677-685.	1.2	7
232	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	15.2	147
233	A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students. <i>BMC Infectious Diseases</i> , 2022, 22, 314.	1.3	2
234	Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre. <i>PLoS ONE</i> , 2022, 17, e0265130.	1.1	23
236	Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers. <i>Scientific Reports</i> , 2022, 12, 5156.	1.6	7

#	ARTICLE	IF	CITATIONS
237	Sensitivity Affected by Disease Severity and Serum Sampling Time: a Performance Evaluation of Six SARS-CoV-2 Antibody Immunoassays. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 388-394.	0.5	1
238	Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms. <i>Cells</i> , 2022, 11, 1182.	1.8	10
239	RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein. <i>Biomicrofluidics</i> , 2022, 16, 024105.	1.2	2
240	Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, e0039622.	1.2	6
241	Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. <i>Journal of Infection</i> , 2022, 84, 814-824.	1.7	8
242	Safety, tolerability, and antibody response after intradermal vaccination of PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine). <i>Vaccine: X</i> , 2022, 10, 100148.	0.9	4
243	SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e057846.	0.8	14
244	Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up. <i>Frontiers in Public Health</i> , 2021, 9, 801609.	1.3	5
245	Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. <i>PLoS ONE</i> , 2021, 16, e0261003.	1.1	24
247	The role and diagnostic accuracy of serology for COVID-19. <i>BMC Infectious Diseases</i> , 2022, 22, 390.	1.3	5
248	A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 Pandemic. <i>Annals of Emergency Medicine</i> , 2022, 80, 38-45.	0.3	8
249	Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI). <i>Journal of Infectious Diseases</i> , 2022, 226, 1877-1881.	1.9	5
253	Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. <i>Journal of Neurology</i> , 2022, 269, 4000-4012.	1.8	9
255	Detecting anti-SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion. <i>Science Advances</i> , 2022, 8, eabn7424.	4.7	14
256	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) <i>Tj ETQq0 0 0 rgt/Overlock 10 Tf 50</i>	0.8	3
257	Development of novel spectroscopic and machine learning methods for the measurement of periodic changes in COVID-19 antibody level. <i>Measurement: Journal of the International Measurement Confederation</i> , 2022, 196, 111258.	2.5	21
258	SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COMMUNITY Cohort Study protocol. <i>BMJ Open</i> , 2022, 12, e061345.	0.8	2
259	Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE). <i>RMD Open</i> , 2022, 8, e002301.	1.8	4

#	ARTICLE	IF	CITATIONS
260	German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. <i>Communications Medicine</i> , 2022, 2, .	1.9	6
261	Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection. <i>Nature Aging</i> , 0, , .	5.3	4
263	Comparison of Four Systems for SARS-CoV-2 Antibody at Three Time Points after SARS-CoV-2 Vaccination. <i>Diagnostics</i> , 2022, 12, 1349.	1.3	0
264	Evaluation of a Multiplex Bead Assay against Single-Target Assays for Detection of IgG Antibodies to SARS-CoV-2. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
265	The influence of time on the sensitivity of SARS-CoV-2 serological testing. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
266	SARS-CoV-2 Seroprevalence, Cumulative Infections, and Immunity to Symptomatic Infection â€œ A Multistage National Household Survey and Modeling Study, Dominican Republic, Juneâ€œOctober 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
267	MoniCovid: Monitoring System for Patients with Symptoms of COVID-19. , 2022, , .		0
268	SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection. <i>Nature Communications</i> , 2022, 13, .	5.8	6
269	Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. <i>Viruses</i> , 2022, 14, 1491.	1.5	13
270	Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e461-e469.	2.0	17
271	SARS-CoV-2 seropositivity and COVID-19 among 5 years-old Amazonian children and their association with poverty and food insecurity. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010580.	1.3	1
272	Ultrasensitive multiplexed chemiluminescent enzyme-linked immunosorbent assays in 384-well plates. <i>Journal of Immunological Methods</i> , 2022, 508, 113311.	0.6	1
273	Evaluation of the performance of multiple immunoassay diagnostic platforms on the National Microbiology Laboratory SARS-CoV-2 National Serology Panel. <i>Jammi</i> , 0, , .	0.3	3
274	Perspective Chapter: Microfluidic Technologies for On-Site Detection and Quantification of Infectious Diseases - The Experience with SARS-CoV-2/COVID-19. <i>Infectious Diseases</i> , 0, , .	4.0	0
275	Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
276	Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
277	SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway. <i>PLoS ONE</i> , 2022, 17, e0264667.	1.1	6
278	A CRISPR-based ultrasensitive assay detects attomolar concentrations of SARS-CoV-2 antibodies in clinical samples. <i>Nature Communications</i> , 2022, 13, .	5.8	24

#	ARTICLE	IF	CITATIONS
279	Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort. <i>International Journal of Infectious Diseases</i> , 2022, 123, 104-111.	1.5	26
280	A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital. <i>Journal of Infection</i> , 2022, 85, 557-564.	1.7	7
281	Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease. <i>Virology</i> , 2022, 575, 83-90.	1.1	1
282	Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology. <i>Journal of Clinical Pathology</i> , 2023, 76, 770-777.	1.0	1
283	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 1525-1538.	3.9	13
284	SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna® vaccinated patients on maintenance immunoapheresis – a cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
285	Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 Infection. <i>Microbiology Spectrum</i> , 0, , .	1.2	2
286	Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	19
287	Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. <i>Nature Communications</i> , 2022, 13, .	5.8	15
288	SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. <i>Nature Communications</i> , 2022, 13, .	5.8	37
289	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1
291	Preanalytical stability of SARS-CoV-2 anti-nucleocapsid antibodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, .	1.4	0
292	A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies. <i>Analytica Chimica Acta</i> , 2023, 1238, 340633.	2.6	2
293	Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study. <i>BMJ Open</i> , 2022, 12, e063159.	0.8	3
294	Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
295	SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021. <i>The Lancet Regional Health Americas</i> , 2022, 16, 100390.	1.5	2
296	Antibody tests for identification of current and past infection with SARS-CoV-2. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	32
297	Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1948.	2.1	3

#	ARTICLE	IF	CITATIONS
298	Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis. EBioMedicine, 2023, 87, 104411.	2.7	2
300	SARS-CoV-2 Serology: Utility and Limits of Different Antigen-Based Tests through the Evaluation and the Comparison of Four Commercial Tests. Biomedicines, 2022, 10, 3106.	1.4	0
301	SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study. BMJ Open, 2022, 12, e066766.	0.8	2
302	One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine. Vaccine, 2022, , .	1.7	4
303	Evaluating the value of anti-SARS-CoV-2 antibody detection and neutralizing responses with euvirus: a population of 10776 close contacts in the epidemic of Fujian. Clinica Chimica Acta, 2022, , .	0.5	0
304	Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. IScience, 2023, 26, 105928.	1.9	5
305	Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity. Cureus, 2023, , .	0.2	0
306	High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India. Indian Journal of Gastroenterology, 2023, 42, 70-78.	0.7	2
307	Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021â€“August 2022. Emerging Infectious Diseases, 2023, 29, 723-733.	2.0	1
308	Real-world performance of SARS-Cov-2 serology tests in the United States, 2020. PLoS ONE, 2023, 18, e0279956.	1.1	0
309	Reply to Brandt et al., â€œAntibodies to Nucleocapsid Are Not Diagnostic for Long COVIDâ€ Microbiology Spectrum, 2023, 11, .	1.2	0
310	Editorial: Current research on serological analyses of infectious diseases. Frontiers in Medicine, 0, 10, .	1.2	2
311	Optimal classification and generalized prevalence estimates for diagnostic settings with more than two classes. Mathematical Biosciences, 2023, 358, 108982.	0.9	0
314	Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. Communications Medicine, 2023, 3, .	1.9	3
315	Research progress of severe acute respiratory syndrome coronavirus 2 on aerosol collection and detection. Chinese Chemical Letters, 2024, 35, 108378.	4.8	0